Zurich Cantonal Bank
SRPT icon

Zurich Cantonal Bank’s Sarepta Therapeutics SRPT Stock Holding History

Zurich Cantonal Bank’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,454
Closed -$655K – 3388
2025
Q4 		$655K Buy
+30,454
New +$642K ﹤0.01% 1607

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zurich Cantonal Bank's SRPT Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 36,221 shares worth $788K. The stake represents ﹤0.01% of the portfolio and ranks #1569 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in SRPT as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in SRPT in Q2 2015 and has held it in 43 quarters since. The position peaked at $4.37M in Q4 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Zurich Cantonal Bank held 36,221 shares of Sarepta Therapeutics worth $788K as of Q1 2026.
  • Sarepta Therapeutics was a new Zurich Cantonal Bank position in Q1 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1569 holding.
  • Zurich Cantonal Bank first reported a position in Sarepta Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Zurich Cantonal Bank's Sarepta Therapeutics position peaked at $4.37M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.